{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:08:03Z","timestamp":1763388483220},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T00:00:00Z","timestamp":1158019200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1038\/sj.bjc.6603329","type":"journal-article","created":{"date-parts":[[2006,9,12]],"date-time":"2006-09-12T12:57:20Z","timestamp":1158065840000},"page":"782-787","source":"Crossref","is-referenced-by-count":17,"title":["Preoperative elevation of serum C \u2013 reactive protein is predictive for prognosis in myeloma bone disease after surgery"],"prefix":"10.1038","volume":"95","author":[{"given":"A","family":"Zahlten-Hinguranage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F W","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bernd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Zeifang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,9,12]]},"reference":[{"key":"BF6603329_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ajh.10304","volume":"72","author":"MG Alexandrakis","year":"2003","unstructured":"Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS (2003) Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 72: 229\u2013233","journal-title":"Am J Hematol"},{"key":"BF6603329_CR2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","volume":"80","author":"R Bataille","year":"1992","unstructured":"Bataille R, Boccadoro M, Klein B, Durie B, Pileri A (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733\u2013737","journal-title":"Blood"},{"key":"BF6603329_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.beha.2005.03.001","volume":"18","author":"JR Berenson","year":"2005","unstructured":"Berenson JR (2005) Myeloma bone disease. Best Pract Res Clin Haematol 18: 653\u2013672","journal-title":"Best Pract Res Clin Haematol"},{"key":"BF6603329_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1046\/j.1365-2362.1998.00333.x","volume":"28","author":"L Biro","year":"1998","unstructured":"Biro L, Domjan G, Falus A, Jakab L, Cseh K, Kalabay L, Tarkovacs G, Tresch J, Malless E, Kramer J, Prohaszka Z, Jako J, F\u00fcst G, Csaszar A (1998) Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest 28: 679\u2013686","journal-title":"Eur J Clin Invest"},{"key":"BF6603329_CR5","first-page":"379","volume":"4","author":"BG Durie","year":"2003","unstructured":"Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoror M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gaharton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Okel M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol 4: 379\u2013398","journal-title":"Hematol"},{"key":"BF6603329_CR6","first-page":"111","volume":"7","author":"HL Frankel","year":"1969","unstructured":"Frankel HL (1969) Ascending cord lesion in the early stages following spinal injuries. Paraplegia 7: 111\u2013118","journal-title":"Paraplegia"},{"key":"BF6603329_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","volume":"132","author":"A Glasmacher","year":"2006","unstructured":"Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmid-Wolf I, Gorschluter M (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132: 584\u2013593","journal-title":"Br J Haematol"},{"key":"BF6603329_CR8","unstructured":"Goldschmidt H, HD-2 Studie der German-Speaking Myeloma Multicenter Group (GMMG) (2003) Einmalige vs zweimalige Hochdosistherapie de Multiplen Myelomas. Deutsche Krebshilfe (Eds). Forum DGK1"},{"key":"BF6603329_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1600-0609.1990.tb00457.x","volume":"45","author":"E Hannisdal","year":"1990","unstructured":"Hannisdal E, Kildahl-Andersen O, Grottum KA, Lamvik J (1990) Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol 45: 198\u2013202","journal-title":"Eur J Haematol"},{"key":"BF6603329_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/cncr.20976","volume":"103","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K (2005) The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856\u20131864. DOI: 10.1002\/cncr.20976","journal-title":"Cancer"},{"key":"BF6603329_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00277-001-0388-5","volume":"81","author":"M Kaneko","year":"2002","unstructured":"Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto M, Chizuka R, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A (2002) Simple prognostic model for patients with multiple myeloma: a single-center study in Japan. Ann Hematol 81: 33\u201336","journal-title":"Ann Hematol"},{"key":"BF6603329_CR12","first-page":"2581","volume":"3","author":"R Kurzrock","year":"1997","unstructured":"Kurzrock R (1997) Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res 3: 2581\u20132584","journal-title":"Clin Cancer Res"},{"key":"BF6603329_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0925-5710(97)00055-8","volume":"66","author":"D Kyriakou","year":"1997","unstructured":"Kyriakou D, Papadaki H, Eliopoulos AG, Foudoulakis A, Alexandrakis M, Eliopoulos GD (1997) Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein. Int J Hematol 66: 367\u2013371","journal-title":"Int J Hematol"},{"key":"BF6603329_CR14","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/cncr.11072","volume":"97","author":"VM Lauta","year":"2003","unstructured":"Lauta VM (2003) A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440\u20132452","journal-title":"Cancer"},{"key":"BF6603329_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/10428199809059228","volume":"31","author":"E Legouffe","year":"1998","unstructured":"Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 31: 351\u2013357","journal-title":"Leuk Lymphoma"},{"key":"BF6603329_CR16","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood.V77.12.2794.2794","volume":"77","author":"H Ludwig","year":"1991","unstructured":"Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H (1991) Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77: 2794\u20132795","journal-title":"Blood"},{"key":"BF6603329_CR17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00003086-198912000-00027","volume":"249","author":"H Mirels","year":"1989","unstructured":"Mirels H (1989) Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop 249: 256\u2013264","journal-title":"Clin Orthop"},{"key":"BF6603329_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.bjc.6602341","volume":"92","author":"GJ Morgan","year":"2005","unstructured":"Morgan GJ, Davies FE (2005) Evolving treatment strategies for myeloma. Br J Cancer 92: 217\u2013221","journal-title":"Br J Cancer"},{"key":"BF6603329_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/BF01714900","volume":"2","author":"DM Nachbaur","year":"1991","unstructured":"Nachbaur DM, Herold M, Maneschg A, Huber H (1991) Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 2: 54\u201358","journal-title":"Ann Hematol"},{"key":"BF6603329_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ijc.10343","volume":"99","author":"H Nakanishi","year":"2002","unstructured":"Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H (2002) Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer 99: 167\u2013170","journal-title":"Int J Cancer"},{"key":"BF6603329_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0002-9610(98)00204-9","volume":"176","author":"T Nozoe","year":"1998","unstructured":"Nozoe T, Matsumata T, Kitamura M, Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335\u2013338","journal-title":"Am J Surg"},{"key":"BF6603329_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000203682","volume":"97","author":"H Papadaki","year":"1997","unstructured":"Papadaki H, Kyriakou D, Foudoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD (1997) Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 97: 191\u2013195","journal-title":"Acta Haematol"},{"key":"BF6603329_CR23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1182\/blood.V85.3.765.bloodjournal853765","volume":"85","author":"TT Pelliniemi","year":"1995","unstructured":"Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajam\u00e4ki A, Tienhaara A, Laakso M, Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85: 765\u2013771","journal-title":"Blood"},{"key":"BF6603329_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1365-2141.1996.d01-1470.x","volume":"92","author":"K Pulkki","year":"1996","unstructured":"Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1996) Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 92: 370\u2013374","journal-title":"Br J Haematol"},{"key":"BF6603329_CR25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.4065\/80.10.1371","volume":"80","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA (2005) Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 80: 1371\u20131382","journal-title":"Mayo Clin Proc"},{"key":"BF6603329_CR26","first-page":"189ff","volume-title":"Myeloma, Biology and Management","author":"FJ San Miguel","year":"2004","unstructured":"San Miguel FJ, Fonseca R, Greipp PR (2004) Prognostic factors and classification for multiple myeloma (contribution to clinical management). In Malpas JS (ed) Myeloma, Biology and Management. Philadelphia: Saunders, p 189ff"},{"key":"BF6603329_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/jso.10275","volume":"83","author":"H Shimada","year":"2003","unstructured":"Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83: 248\u2013252","journal-title":"J Surg Oncol"},{"key":"BF6603329_CR28","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1860::AID-CNCR7>3.0.CO;2-R","volume":"82","author":"R Stasi","year":"1998","unstructured":"Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A (1998) The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer 82: 1860\u20131866","journal-title":"Cancer"},{"key":"BF6603329_CR29","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"ER Terpos","year":"2003","unstructured":"Terpos ER, Szydlo JF, Apperley E, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman J, Rahemtulla A (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064\u20131069","journal-title":"Blood"},{"key":"BF6603329_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2141.1994.tb04748.x","volume":"86","author":"A Tienhaara","year":"1994","unstructured":"Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi TT (1994) Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol 86: 391\u2013393","journal-title":"Br J Haematol"},{"key":"BF6603329_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.2004.04851.x","volume":"25","author":"G Tricot","year":"2004","unstructured":"Tricot G, Barlogie B, van Rhee F (2004) Treatment advances in multiple myeloma. Haemataol 25: 24\u201330","journal-title":"Haemataol"},{"key":"BF6603329_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1046\/j.1365-2141.1998.00538.x","volume":"100","author":"M Yamamura","year":"1998","unstructured":"Yamamura M, Yamada Y, Momita S, Kamihira S, Tomonaga M (1998) Circulating interleukin-6 levels are elevated in adult T-cell leukaemia\/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 100: 129\u2013134","journal-title":"Br J Haematol"},{"key":"BF6603329_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/annoc\/mdi054","volume":"16","author":"F Zeifang","year":"2005","unstructured":"Zeifang F, Zahlten-Hinguranage A, Goldschmidt H, Cremer F, Bernd L, Sabo D (2005) Long-term survival after surgical intervention for bone disease in multiple myeloma. Ann Oncol 16: 222\u2013227, DOI:10.1093\/annoc\/mdi054","journal-title":"Ann Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6603329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603329","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6603329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:22:59Z","timestamp":1684412579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6603329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,12]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["BF6603329"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6603329","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,12]]}}}